

Efficacy and effectiveness of an rVSV-vectored vaccine final results from the Guinea ring vaccination, open-lab

Lancet, The

389, 505-518

DOI: [10.1016/s0140-6736\(16\)32621-6](https://doi.org/10.1016/s0140-6736(16)32621-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 330-341.	13.9	314
2	CEPI—a new global R&D organisation for epidemic preparedness and response. <i>Lancet</i> , The, 2017, 389, 233-235.	6.3	100
3	Persistence of immune responses induced by Ebola virus vaccines. <i>The Lancet Global Health</i> , 2017, 5, e238-e239.	2.9	2
4	Multivalent Glycosylated Nanostructures To Inhibit Ebola Virus Infection. <i>Journal of the American Chemical Society</i> , 2017, 139, 6018-6025.	6.6	104
5	Contact tracing performance during the Ebola virus disease outbreak in Kenema district, Sierra Leone. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160300.	1.8	23
6	On the wrong side of history. <i>Nature Microbiology</i> , 2017, 2, 17046.	5.9	5
7	Key data for outbreak evaluation: building on the Ebola experience. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160371.	1.8	70
8	The Ebola outbreak, 2013–2016: old lessons for new epidemics. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160297.	1.8	315
9	A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	48
10	Emerging sexually transmitted viral infections: 1. Review of Ebola virus disease. <i>International Journal of STD and AIDS</i> , 2017, 28, 1352-1359.	0.5	5
11	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	2.6	15
12	Progress in Ebola Virus Vaccine Development. <i>Journal of Infectious Diseases</i> , 2017, 215, 1775-1776.	1.9	2
13	Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 585-604.	2.0	28
14	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. <i>EBioMedicine</i> , 2017, 19, 107-118.	2.7	64
15	Lessons learned by surveillance during the tail-end of the Ebola outbreak in Guinea, June-October 2015: a case series. <i>BMC Infectious Diseases</i> , 2017, 17, 304.	1.3	4
16	Ebola and Marburg virus vaccines. <i>Virus Genes</i> , 2017, 53, 501-515.	0.7	70
17	Insights from clinical research completed during the west Africa Ebola virus disease epidemic. <i>Lancet Infectious Diseases</i> , The, 2017, 17, e280-e292.	4.6	69
18	Screening of commercial cyclic peptide conjugated to HIV-1 Tat peptide as inhibitor of N-terminal heptad repeat glycoprotein-2 ectodomain Ebola virus through in silico analysis. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 74, 366-378.	1.3	18

#	ARTICLE	IF	CITATIONS
19	Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
20	Advances in Ebola virus vaccination. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 787-788.	4.6	2
21	Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
22	Safety and immunogenicity of the rVSVΔ ^{GP} -ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 854-866.	4.6	105
23	WHO ready to deploy Ebola vaccine in disease outbreak. <i>BMJ: British Medical Journal</i> , 2017, 357, j2454.	2.4	2
24	Ebola Virus Delta Peptide Is a Viroporin. <i>Journal of Virology</i> , 2017, 91, .	1.5	26
25	Closer than ever to an Ebola virus vaccine. <i>Expert Review of Vaccines</i> , 2017, 16, 401-402.	2.0	5
26	Generation and characterization of protective antibodies to Marburg virus. <i>MAbs</i> , 2017, 9, 696-703.	2.6	28
27	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	1.4	67
28	West Africa 2013 Ebola: From Virus Outbreak to Humanitarian Crisis. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 63-92.	0.7	19
29	An effective and safe vaccine will not be enough to prepare us for the next Ebola outbreak. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1224-1225.	4.6	4
30	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	13.9	199
31	We Can Do Better – Improving Outcomes in the Midst of an Emergency. <i>New England Journal of Medicine</i> , 2017, 377, 1482-1484.	13.9	13
33	Plant-made vaccines and reagents for the One Health initiative. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2912-2917.	1.4	39
34	Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2918-2930.	1.4	33
35	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. <i>Cell Reports</i> , 2017, 20, 2251-2261.	2.9	107
36	Recent advances in vaccine development against Ebola threat as bioweapon. <i>VirusDisease</i> , 2017, 28, 242-246.	1.0	7
37	Windows of opportunity for Ebola virus infection treatment and vaccination. <i>Scientific Reports</i> , 2017, 7, 8975.	1.6	34

#	ARTICLE	IF	CITATIONS
38	An update on ocular complications of Ebola virus disease. <i>Current Opinion in Ophthalmology</i> , 2017, 28, 600-606.	1.3	39
39	Multi-template homology based structure prediction and molecular docking studies of protein GP1 of Zaire ebolavirus (EBOV). <i>Informatics in Medicine Unlocked</i> , 2017, 9, 68-75.	1.9	10
40	WHO R&D Blueprint: a global coordination mechanism for R&D preparedness. <i>Lancet, The</i> , 2017, 389, 2469-2470.	6.3	30
41	Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. <i>Journal of Clinical Immunology</i> , 2017, 37, 650-692.	2.0	6
42	Improving vaccine trials in infectious disease emergencies. <i>Science</i> , 2017, 357, 153-156.	6.0	28
43	Novel Concepts for HIV Vaccine Vector Design. <i>MSphere</i> , 2017, 2, .	1.3	11
44	A review on the antagonist Ebola: A prophylactic approach. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1513-1526.	2.5	13
45	How Vaccinating People Can Also Protect Others. , 2017, , 13-18.		0
46	The story of Canada's Ebola vaccine. <i>Cmaj</i> , 2017, 189, E1326-E1327.	0.9	10
47	Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 1276-1284.	4.6	79
48	Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. <i>Vaccine</i> , 2017, 35, 4465-4469.	1.7	44
49	News Feature: Special agents offer modeling upgrade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7176-7179.	3.3	4
50	Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic. <i>BMC Medical Ethics</i> , 2017, 18, 43.	1.0	50
51	The UK's multidisciplinary response to an Ebola epidemic. <i>Clinical Medicine</i> , 2017, 17, 332-337.	0.8	16
52	Marburg- and Ebolaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	4
53	Biocontaining: Purification, Restoration, and Meaning-Making. <i>Perspectives in Biology and Medicine</i> , 2017, 60, 166-185.	0.3	2
55	The Ebola outbreak and staffing in public health facilities in rural Sierra Leone: who is left to do the job?. <i>Public Health Action</i> , 2017, 7, 47-54.	0.4	11
56	Host Transcriptional Response to Ebola Virus Infection. <i>Vaccines</i> , 2017, 5, 30.	2.1	23

#	ARTICLE	IF	CITATIONS
57	A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus. <i>Frontiers in Immunology</i> , 2017, 8, 252.	2.2	23
58	Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4. <i>Frontiers in Microbiology</i> , 2017, 8, 1571.	1.5	56
59	Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C. <i>Frontiers in Microbiology</i> , 2017, 8, 2413.	1.5	26
60	Lessons Learned from Emergency Response Vaccination Efforts for Cholera, Typhoid, Yellow Fever, and Ebola. <i>Emerging Infectious Diseases</i> , 2017, 23, .	2.0	17
61	Safety and immunogenicity of rVSV ^Δ G-ZEBOV-GP Ebola vaccine in adults and children in Lambaré, Gabon: A phase I randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002402.	3.9	57
63	Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials. <i>Reproductive Health</i> , 2017, 14, 172.	1.2	69
64	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. <i>AIDS Research and Therapy</i> , 2017, 14, 55.	0.7	20
65	Engaging Anthropology in an Ebola Outbreak. <i>Anthropology in Action</i> , 2017, 24, 1-8.	1.1	15
67	Glance at potential future combating of diseases: Bioengineered antimicrobial organisms. <i>Scientific Research and Essays</i> , 2017, 12, 51-58.	0.1	0
68	Viral Infections in Workers in Hospital and Research Laboratory Settings. <i>Annals of Clinical Microbiology</i> , 2017, 20, 27.	0.3	2
69	Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials. <i>American Journal of Epidemiology</i> , 2018, 187, 1763-1771.	1.6	17
70	Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
71	Rigorous Clinical Trial Design in Public Health Emergencies Is Essential. <i>Clinical Infectious Diseases</i> , 2018, 66, 1467-1469.	2.9	20
72	A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. <i>Journal of Virology</i> , 2018, 92, .	1.5	43
73	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 738-748.	4.6	62
74	Measles-derived vaccines to prevent emerging viral diseases. <i>Microbes and Infection</i> , 2018, 20, 493-500.	1.0	44
75	Ebola could be eradicated through voluntary vaccination. <i>Royal Society Open Science</i> , 2018, 5, 171591.	1.1	29
77	Filoviruses and Arenaviruses. , 2018, , 1190-1195.e2.		0

#	ARTICLE	IF	CITATIONS
78	Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 36-44.	2.9	12
79	Post-exposure treatments for Ebola and Marburg virus infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 413-434.	21.5	104
80	Willingness to pay for an Ebola vaccine during the 2014-2016 ebola outbreak in West Africa: Results from a U.S. National sample. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1665-1671.	1.4	20
81	The Stepped-Wedge Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 607.	3.8	21
82	A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. <i>Scientific Reports</i> , 2018, 8, 864.	1.6	43
83	Non-natural amino acid peptide microarrays to discover Ebola virus glycoprotein ligands. <i>Chemical Communications</i> , 2018, 54, 1417-1420.	2.2	5
84	Single-cycle adenovirus vectors in the current vaccine landscape. <i>Expert Review of Vaccines</i> , 2018, 17, 1-11.	2.0	25
85	Ebola vaccines, evidentiary charisma and the rise of global health emergency research. <i>Economy and Society</i> , 2018, 47, 135-161.	1.3	47
86	The current landscape of nucleic acid tests for filovirus detection. <i>Journal of Clinical Virology</i> , 2018, 103, 27-36.	1.6	13
87	Effect of Confusing Symptoms and Infectiousness on Forecasting and Control of Ebola Outbreaks. <i>Clinical Infectious Diseases</i> , 2018, 67, 1472-1474.	2.9	17
88	Good intentions do not replace ethical conduct in research. <i>Lancet, The</i> , 2018, 391, 1020-1021.	6.3	0
89	Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply. <i>Lancet, The</i> , 2018, 391, 1021-1022.	6.3	8
90	Questionable efficacy of the rVSV-ZEBOV Ebola vaccine. <i>Lancet, The</i> , 2018, 391, 1021.	6.3	24
91	Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice. <i>Vaccine</i> , 2018, 36, 3090-3100.	1.7	35
92	Novel viral vectors in infectious diseases. <i>Immunology</i> , 2018, 153, 1-9.	2.0	116
93	Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections. <i>Human Gene Therapy</i> , 2018, 29, 452-466.	1.4	13
94	Disaster Preparedness: Biological Threats and Treatment Options. <i>Pharmacotherapy</i> , 2018, 38, 217-234.	1.2	30
95	Ebola virus disease: an update on post-exposure prophylaxis. <i>Lancet Infectious Diseases, The</i> , 2018, 18, e183-e192.	4.6	112

#	ARTICLE	IF	CITATIONS
96	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opinion on Biological Therapy, 2018, 18, 159-173.	1.4	35
97	Vaccines against Ebola virus. Vaccine, 2018, 36, 5454-5459.	1.7	43
98	Bioinformatics Approach to Screening and Developing Drug against Ebola. , 0, , .		0
99	Ebola virus epidemic disease its modeling and stability analysis required abstain strategies. Cogent Biology, 2018, 4, 1488511.	1.7	11
100	Pre-clinical development of a vaccine against Lassa fever. Canada Communicable Disease Report, 2018, 44, 139-147.	0.6	3
101	Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?. Expert Review of Vaccines, 2018, 17, 1105-1110.	2.0	14
102	Participant Retention in a Randomized Clinical Trial in an Outbreak Setting: Lessons From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE). Journal of Infectious Diseases, 2018, 217, S65-S74.	1.9	5
103	Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola. Journal of Infectious Diseases, 2018, 217, S33-S39.	1.9	5
104	Self-Replicating RNA Viruses for RNA Therapeutics. Molecules, 2018, 23, 3310.	1.7	49
105	Clinical Trials and Administration of Zika Virus Vaccine in Pregnant Women: Lessons (that Should) Tj ETQq1 1 0.784314 rgBT /Overlook Lactation. Vaccines, 2018, 6, 81.	2.1	39
106	Special focus on challenges and opportunities for the development and use of vaccines in Africa. Human Vaccines and Immunotherapeutics, 2018, 14, 2335-2339.	1.4	19
107	Public Health Disaster-Related Research: A Solidaristic Ethical Prism for Understanding Fundersâ€™ Duties. American Journal of Bioethics, 2018, 18, 37-39.	0.5	2
108	Persistence and Sexual Transmission of Filoviruses. Viruses, 2018, 10, 683.	1.5	62
109	Ebola virus epidemic in war-torn eastern DR Congo. Lancet, The, 2018, 392, 1399-1401.	6.3	54
110	Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nature Communications, 2018, 9, 4013.	5.8	54
111	Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV. Vaccine, 2018, 36, 7083-7094.	1.7	6
112	Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program. Expert Review of Vaccines, 2018, 17, 913-923.	2.0	9
113	Measles: is a new vaccine approach needed?. Lancet Infectious Diseases, The, 2018, 18, 1060-1061.	4.6	13

#	ARTICLE	IF	CITATIONS
114	High-resolution epidemic simulation using within-host infection and contact data. BMC Public Health, 2018, 18, 886.	1.2	21
115	Global Bioheroes: clinical research and new vaccines for health security. Australian Journal of International Affairs, 2018, 72, 584-601.	0.8	2
116	Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. The Lancet Global Health, 2018, 6, e1386-e1396.	2.9	205
117	A Radical Approach to Ebola: Saving Humans and Other Animals. American Journal of Bioethics, 2018, 18, 35-42.	0.5	13
118	Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques. PLoS ONE, 2018, 13, e0202997.	1.1	11
119	From vaccines to global health to vaccines. Human Vaccines and Immunotherapeutics, 2018, 14, 1-3.	1.4	0
120	Mapping HLA-A2, -A3 and -B7 supertype-restricted T-cell epitopes in the ebolavirus proteome. BMC Genomics, 2018, 19, 42.	1.2	18
121	Will a Single-Cycle Adenovirus Vaccine Be Effective Against Ebola Virus?. Journal of Infectious Diseases, 2018, 218, 1858-1860.	1.9	0
122	Infection Rates and Risk Factors for Infection Among Health Workers During Ebola and Marburg Virus Outbreaks: A Systematic Review. Journal of Infectious Diseases, 2018, 218, S679-S689.	1.9	81
123	A Historical Review of Ebola Outbreaks. , 0, , .		4
124	Rapid Establishment of a Cold Chain Capacity of $\leq 60^{\circ}\text{C}$ or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone. Journal of Infectious Diseases, 2018, 217, S48-S55.	1.9	34
125	Ebola: Lessons on Vaccine Development. Annual Review of Microbiology, 2018, 72, 423-446.	2.9	51
126	Rhabdoviruses as vaccine platforms for infectious disease and cancer. Biotechnology and Genetic Engineering Reviews, 2018, 34, 122-138.	2.4	25
127	Keeping Your Cool $\hat{=}$ Doing Ebola Research during an Emergency. New England Journal of Medicine, 2018, 378, 2353-2355.	13.9	5
128	Global Emergency Medicine: A Review of the Literature From 2017. Academic Emergency Medicine, 2018, 25, 1287-1298.	0.8	12
129	The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV Δ g-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. Journal of Infectious Diseases, 2018, 217, S6-S15.	1.9	66
130	Design of vaccine trials during outbreaks with and without a delayed vaccination comparator. Annals of Applied Statistics, 2018, 12, 330-347.	0.5	6
131	The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2107-2113.	1.4	107

#	ARTICLE	IF	CITATIONS
132	Ebola virus disease: 11â€™323 deaths later, how far have we come?. <i>Lancet, The</i> , 2018, 392, 189-190.	6.3	6
133	Outbreak of Ebola virus disease in the Democratic Republic of the Congo, Aprilâ€™May, 2018: an epidemiological study. <i>Lancet, The</i> , 2018, 392, 213-221.	6.3	93
134	Lessons from the West Africa Ebola Epidemic: A Systematic Review of Epidemiological and Social and Behavioral Science Research Priorities. <i>Journal of Infectious Diseases</i> , 2018, 218, 1730-1738.	1.9	22
135	Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006275.	1.3	10
136	Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2018, 218, S582-S587.	1.9	28
137	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. <i>Journal of Infectious Diseases</i> , 2018, 218, S672-S678.	1.9	49
138	Willingness to get vaccinated against Ebola: A mapping of Guinean people positions. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2391-2396.	1.4	16
139	Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa. <i>Intensive Care Medicine</i> , 2018, 44, 1266-1275.	3.9	16
140	Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola. <i>Journal of Infectious Diseases</i> , 2018, 217, S24-S32.	1.9	5
141	A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. <i>Nature Communications</i> , 2018, 9, 3067.	5.8	65
143	A comparative computational genomics of Ebola Virus Disease strains: In-silico Insight for Ebola control. <i>Informatics in Medicine Unlocked</i> , 2018, 12, 106-119.	1.9	15
144	Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling. <i>Frontiers in Microbiology</i> , 2018, 9, 1546.	1.5	61
145	Qualitative Profiling of the Humoral Immune Response Elicited by rVSV-Î”G-EBOV-GP Using a Systems Serology Assay, Domain Programmable Arrays. <i>Cell Reports</i> , 2018, 24, 1050-1059.e5.	2.9	11
146	A VSV-based Zika virus vaccine protects mice from lethal challenge. <i>Scientific Reports</i> , 2018, 8, 11043.	1.6	63
147	The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1428.	2.2	22
148	Correlates of vaccine-induced protective immunity against Ebola virus disease. <i>Seminars in Immunology</i> , 2018, 39, 65-72.	2.7	44
149	Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies. <i>Frontiers in Immunology</i> , 2018, 9, 1025.	2.2	12
150	Merck vaccine heads Ebola countermeasures. <i>Nature Biotechnology</i> , 2018, 36, 563-565.	9.4	2

#	ARTICLE	IF	CITATIONS
151	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. <i>Journal of Infectious Diseases</i> , 2018, 218, S553-S564.	1.9	22
152	Bioemergency Planning. , 2018, , .		0
153	Communicable Diseases and Emerging Pathogens: The Past, Present, and Future of High-Level Containment Care. , 2018, , 1-19.		1
154	What treating Ebola means for pandemic influenza. <i>Journal of Public Health Policy</i> , 2018, 39, 268-282.	1.0	8
155	Cluster-Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-Level Dengue Interventions. <i>American Journal of Epidemiology</i> , 2018, 187, 2021-2028.	1.6	19
156	A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. <i>Journal of Infectious Diseases</i> , 2018, 218, 1883-1889.	1.9	14
157	Prevention of Ebola virus disease through vaccination: where we are in 2018. <i>Lancet, The</i> , 2018, 392, 787-790.	6.3	103
158	Ebola virus “ prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine. <i>Expert Review of Vaccines</i> , 2018, 17, 769-771.	2.0	1
159	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. <i>International Journal of Infectious Diseases</i> , 2018, 74, 83-96.	1.5	21
160	From 1976 to 2018: reflections on early investigations into the Ebola virus. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2018, 112, 527-528.	0.7	11
161	Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus. <i>Frontiers in Immunology</i> , 2018, 9, 1803.	2.2	65
162	Ebola Virus Disease. , 0, , 521-525.		0
163	A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle. <i>Genome Medicine</i> , 2018, 10, 58.	3.6	41
164	Choices in vaccine trial design in epidemics of emerging infections. <i>PLoS Medicine</i> , 2018, 15, e1002632.	3.9	29
165	New Vaccine Technologies to Combat Outbreak Situations. <i>Frontiers in Immunology</i> , 2018, 9, 1963.	2.2	437
166	Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. <i>Viral Immunology</i> , 2018, 31, 500-512.	0.6	3
167	Response to the Ebola virus disease outbreak in the Democratic Republic of the Congo. <i>Lancet, The</i> , 2018, 391, 2395-2398.	6.3	9
168	Recombinant Therapeutic Molecules Produced in Plants. <i>Advances in Botanical Research</i> , 2018, 86, 207-244.	0.5	3

#	ARTICLE	IF	CITATIONS
169	Ebola 2018 – Implications for travel health advice and relevance for travel medicine. <i>Travel Medicine and Infectious Disease</i> , 2018, 24, 1-3.	1.5	3
170	Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. <i>Journal of Virology</i> , 2018, 92, .	1.5	21
171	Ebolaviruses: New roles for old proteins. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006349.	1.3	33
172	Ebola Mysteries and Conundrums. <i>Journal of Infectious Diseases</i> , 2019, 219, 511-513.	1.9	0
173	Emergent threats: lessons learnt from Ebola. <i>International Health</i> , 2019, 11, 334-337.	0.8	29
174	Projections of epidemic transmission and estimation of vaccination impact during an ongoing Ebola virus disease outbreak in Northeastern Democratic Republic of Congo, as of Feb. 25, 2019. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007512.	1.3	17
175	Self-amplifying RNA virus vectors: clinical applications in cancer drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 1027-1029.	2.4	6
176	Ebola vaccine innovation: a case study of pseudoscapes in global health. <i>Critical Public Health</i> , 2019, 29, 401-412.	1.4	11
177	Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge. <i>Journal of Infectious Diseases</i> , 2019, 220, 1521-1528.	1.9	12
178	Neurologic Infections in Travelers. <i>Seminars in Neurology</i> , 2019, 39, 399-414.	0.5	1
179	Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2269-2285.	1.4	58
180	Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007595.	1.3	38
181	Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context. <i>Trials</i> , 2019, 20, 422.	0.7	4
182	Immunogenicity, Lot Consistency, and Extended Safety of rVSV-G-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2019, 220, 1127-1135.	1.9	42
183	The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection. <i>Scientific Reports</i> , 2019, 9, 10471.	1.6	13
184	Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. <i>Vaccine</i> , 2019, 37, 6942-6950.	1.7	15
185	Therapeutic strategies to target the Ebola virus life cycle. <i>Nature Reviews Microbiology</i> , 2019, 17, 593-606.	13.6	110
186	Polyphenylene carboxymethylene (PPCM) in vitro antiviral efficacy against Ebola virus in the context of a sexually transmitted infection. <i>Antiviral Research</i> , 2019, 170, 104567.	1.9	8

#	ARTICLE	IF	CITATIONS
187	Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine. <i>MBio</i> , 2019, 10, .	1.8	4
188	Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2249-2257.	1.4	5
189	Design of vaccine efficacy trials during public health emergencies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	41
190	Vaccines and global health: In search of a sustainable model for vaccine development and delivery. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	88
191	An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. <i>Vaccine</i> , 2019, 37, 4376-4381.	1.7	11
192	Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins. <i>Pathogens</i> , 2019, 8, 192.	1.2	3
193	Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2359-2377.	1.4	31
194	Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. <i>Nature Medicine</i> , 2019, 25, 1589-1600.	15.2	92
195	Ebola virus disease preparedness and response in Central East Africa. <i>Medical Journal of Australia</i> , 2019, 211, 449.	0.8	0
196	CEPI: Driving Progress Toward Epidemic Preparedness and Response. <i>Epidemiologic Reviews</i> , 2019, 41, 28-33.	1.3	70
197	Postexposure Effects of Vaccines on Infectious Diseases. <i>Epidemiologic Reviews</i> , 2019, 41, 13-27.	1.3	25
198	When Is It Acceptable to Vaccinate Pregnant Women? Risk, Ethics, and Politics of Governance in Epidemic Crises. <i>Current Tropical Medicine Reports</i> , 2019, 6, 205-212.	1.6	4
199	A new twenty-first century science for effective epidemic response. <i>Nature</i> , 2019, 575, 130-136.	18.7	211
200	Ebola virus-mediated T-lymphocyte depletion is the result of an abortive infection. <i>PLoS Pathogens</i> , 2019, 15, e1008068.	2.1	34
201	Recent Advances in the Diagnosis and Management of Ebola Virus Disease. <i>Clinical Microbiology Newsletter</i> , 2019, 41, 185-189.	0.4	5
202	Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge. <i>EBioMedicine</i> , 2019, 49, 223-231.	2.7	34
204	The Role of Reference Materials in the Research and Development of Diagnostic Tools and Treatments for Haemorrhagic Fever Viruses. <i>Viruses</i> , 2019, 11, 781.	1.5	7
205	Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection. <i>ACS Nano</i> , 2019, 13, 11087-11096.	7.3	33

#	ARTICLE	IF	CITATIONS
206	Regulatory aspects of quality and safety for live recombinant viral vaccines against infectious diseases in Japan. <i>Vaccine</i> , 2019, 37, 6573-6579.	1.7	6
207	Subsequent mortality in survivors of Ebola virus disease in Guinea: a nationwide retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1202-1208.	4.6	16
208	Host protein mimics viral protein to hinder infection by Ebola virus. <i>Nature</i> , 2019, 566, 190-191.	13.7	0
209	Modelling microbial infection to address global health challenges. <i>Nature Microbiology</i> , 2019, 4, 1612-1619.	5.9	34
210	UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments. <i>Vaccine</i> , 2019, 37, 6241-6247.	1.7	13
211	Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition. <i>Frontiers in Microbiology</i> , 2019, 10, 2145.	1.5	14
212	Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells. <i>Vaccine</i> , 2019, 37, 6624-6632.	1.7	25
213	Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	53
214	Ebola Virus: Pathogenesis and Countermeasure Development. <i>Annual Review of Virology</i> , 2019, 6, 435-458.	3.0	50
215	A glimpse into immune responses evolving against Ebola virus. <i>Nature Medicine</i> , 2019, 25, 1470-1471.	15.2	7
216	Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses. <i>Viruses</i> , 2019, 11, 856.	1.5	7
217	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	1.9	59
218	Health care worker vaccination against Ebola: Vaccine acceptance and employment duration in Sierra Leone. <i>Vaccine</i> , 2019, 37, 1101-1108.	1.7	10
219	Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus. <i>Npj Vaccines</i> , 2019, 4, 5.	2.9	45
220	International Biological Reference Preparations for Epidemic Infectious Diseases. <i>Emerging Infectious Diseases</i> , 2019, 25, 205-211.	2.0	11
221	Maternal and Infant Survival Following Ebola Infection: Their Exclusion from Treatment and Vaccine Trials and "Primum non nocere". <i>Global Maternal and Child Health</i> , 2019, , 147-155.	0.1	2
222	Vaccine Trials in Schools: We Must Not Ignore Progress. <i>American Journal of Public Health</i> , 2019, 109, 219-220.	1.5	0
223	A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. <i>Nature Communications</i> , 2019, 10, 285.	5.8	46

#	ARTICLE	IF	CITATIONS
224	New and Emerging Infections: a Select Review of Evolving Pathogens. Current Treatment Options in Pediatrics, 2019, 5, 284-292.	0.2	1
225	Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever. Scientific Reports, 2019, 9, 7755.	1.6	43
226	Pharmacoevidence: Using randomised control trials and observational studies in clinical decision-making. British Journal of Clinical Pharmacology, 2019, 85, 1907-1924.	1.1	15
227	The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018-2019. New England Journal of Medicine, 2019, 381, 373-383.	13.9	129
228	Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease. Emerging Infectious Diseases, 2019, 25, 1144-1152.	2.0	41
229	Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS ONE, 2019, 14, e0215457.	1.1	35
230	Ebola vaccines: ready to use for humanitarian health workers?. Journal of Travel Medicine, 2019, 26, .	1.4	3
232	Emerging Infectious Diseases and Antimicrobial Resistance (EIDAR). Military Medicine, 2019, 184, 59-65.	0.4	2
233	rVSV-G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment. Vaccine: X, 2019, 1, 100009.	0.9	61
234	Ebola vaccination in the Democratic Republic of the Congo. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10178-10183.	3.3	38
235	Protein and Glycan Mimicry in HIV Vaccine Design. Journal of Molecular Biology, 2019, 431, 2223-2247.	2.0	91
236	Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. Journal of Infectious Diseases, 2019, 220, 400-410.	1.9	91
237	Vaccine vectors: the bright side of cytomegalovirus. Medical Microbiology and Immunology, 2019, 208, 349-363.	2.6	23
238	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nature Microbiology, 2019, 4, 734-747.	5.9	158
239	Achieving cross-reactivity with pan-ebolavirus antibodies. Current Opinion in Virology, 2019, 34, 140-148.	2.6	18
240	Emerging Challenges and Opportunities in Infectious Disease Epidemiology. American Journal of Epidemiology, 2019, 188, 873-882.	1.6	14
241	RNA Viruses as Tools in Gene Therapy and Vaccine Development. Genes, 2019, 10, 189.	1.0	51
242	Design of a multi-epitopic Zaire ebolavirus protein and its expression in plant cells. Journal of Biotechnology, 2019, 295, 41-48.	1.9	10

#	ARTICLE	IF	CITATIONS
243	Development and characterization of a Zaire Ebola (ZEBOV) specific IgM ELISA. <i>Journal of Immunological Methods</i> , 2019, 468, 29-34.	0.6	3
244	Unprecedented Thiocalixarene Fucoclusters as Strong Inhibitors of Ebola cis-Cell Infection and HCMV-gB Glycoprotein/DC-SIGN C-type Lectin Interaction. <i>Bioconjugate Chemistry</i> , 2019, 30, 1114-1126.	1.8	16
245	Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors. <i>Frontiers in Immunology</i> , 2019, 10, 372.	2.2	57
246	Control of Ebola virus disease outbreaks: Comparison of health care worker-targeted and community vaccination strategies. <i>Epidemics</i> , 2019, 27, 106-114.	1.5	13
247	Projections of Ebola outbreak size and duration with and without vaccine use in Mbandaka, Democratic Republic of Congo, as of May 27, 2018. <i>PLoS ONE</i> , 2019, 14, e0213190.	1.1	23
248	A Diacylglycerol Kinase Inhibitor, R-59-022, Blocks Filovirus Internalization in Host Cells. <i>Viruses</i> , 2019, 11, 206.	1.5	8
249	Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus " Zaire Ebolavirus Vaccine. <i>Vaccine</i> , 2019, 37, 2174-2178.	1.7	22
250	Maximum Containment Infectious Disease Laboratories as an Integral Part of Emergency Preparedness and Emergency Response. , 2019, , 125-144.		0
251	Innate sensors that regulate vaccine responses. <i>Current Opinion in Immunology</i> , 2019, 59, 31-41.	2.4	21
253	In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice. <i>Vaccines</i> , 2019, 7, 34.	2.1	43
254	Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules. <i>Medical Microbiology and Immunology</i> , 2019, 208, 227-238.	2.6	16
255	Role of Type I Interferons on Filovirus Pathogenesis. <i>Vaccines</i> , 2019, 7, 22.	2.1	6
256	Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. <i>Journal of Infectious Diseases</i> , 2019, 220, 57-67.	1.9	75
257	Bats and Viruses: Emergence of Novel Lyssaviruses and Association of Bats with Viral Zoonoses in the EU. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 31.	0.9	51
258	Guns " viruses. <i>Microbes and Infection</i> , 2019, 21, 125-128.	1.0	1
259	Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines. <i>Health Security</i> , 2019, 17, 46-53.	0.9	5
260	Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation. <i>Frontiers in Immunology</i> , 2018, 9, 3071.	2.2	38
261	Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. <i>Journal of Infectious Diseases</i> , 2019, 220, 46-56.	1.9	117

#	ARTICLE	IF	CITATIONS
262	Modeling Ebola Virus Infection. , 2019, , 85-103.		0
264	Pseudovirus rVSV ^{GP} -ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice. <i>Cell Reports</i> , 2019, 26, 1718-1726.e4.	2.9	29
265	Perceptions and acceptability of an experimental Ebola vaccine among health care workers, frontline staff, and the general public during the 2014â€“2015 Ebola outbreak in Sierra Leone. <i>Vaccine</i> , 2019, 37, 1495-1502.	1.7	8
266	Ebola virus disease. <i>Lancet, The</i> , 2019, 393, 936-948.	6.3	305
267	Diagnostics for filovirus detection: impact of recent outbreaks on the diagnostic landscape. <i>BMJ Global Health</i> , 2019, 4, e001112.	2.0	18
268	Role of retroviral vector-based interventions in combating virus infections. <i>Future Virology</i> , 2019, 14, 473-485.	0.9	0
269	Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 219, 544-555.	1.9	30
270	Ebola Virus Disease. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 953-976.	1.9	36
271	Ebola vaccine trials: progress in vaccine safety and immunogenicity. <i>Expert Review of Vaccines</i> , 2019, 18, 1229-1242.	2.0	61
272	Pregnant Women, Vaccine Development for Emerging and Epidemic Viral Infections and Maternal Immunization: Human Rights and the Global Survival of Mothers and Infants. <i>Current Tropical Medicine Reports</i> , 2019, 6, 179-185.	1.6	5
273	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. <i>Cell Reports</i> , 2019, 29, 2537-2545.e3.	2.9	7
275	Immunization: vital progress, unfinished agenda. <i>Nature</i> , 2019, 575, 119-129.	13.7	126
276	Study protocol for the multicentre cohorts of Zika virus infection in pregnant women, infants, and acute clinical cases in Latin America and the Caribbean: the ZIKAlliance consortium. <i>BMC Infectious Diseases</i> , 2019, 19, 1081.	1.3	11
277	The global forum on bioethics in research meeting, â€œethics of alternative clinical trial designs and methods in low- and middle-income country researchâ€“ emerging themes and outputs. <i>Trials</i> , 2019, 20, 701.	0.7	13
278	Viral Hemorrhagic Fevers in Pregnant Women and the Vaccine Landscape: Comparisons Between Yellow Fever, Ebola, and Lassa Fever. <i>Current Tropical Medicine Reports</i> , 2019, 6, 186-196.	1.6	10
279	Maternal and Infant Death and the rVSV-ZEBOV Vaccine Through Three Recent Ebola Virus Epidemics-West Africa, DRC <i>Ã</i> quateur and DRC Kivu: 4 Years of Excluding Pregnant and Lactating Women and Their Infants from Immunization. <i>Current Tropical Medicine Reports</i> , 2019, 6, 213-222.	1.6	17
280	A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice. <i>Viruses</i> , 2019, 11, 1149.	1.5	11
282	Ebola and State Legitimacy. <i>Economic Journal</i> , 2019, 129, 2064-2089.	1.9	29

#	ARTICLE	IF	CITATIONS
283	Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. Trends in Microbiology, 2019, 27, 8-16.	3.5	32
284	Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets. Antiviral Research, 2019, 162, 90-100.	1.9	12
285	A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B. Journal of Virology, 2019, 93, .	1.5	10
286	Current Ebola Virus Vaccine Progress. BioDrugs, 2019, 33, 9-14.	2.2	32
287	The threat of bioterrorism. Lancet Infectious Diseases, The, 2019, 19, 18-19.	4.6	7
288	Perspectives towards antiviral drug discovery against Ebola virus. Journal of Medical Virology, 2019, 91, 2029-2048.	2.5	35
289	Host and Viral Proteins Modulating Ebola and Marburg Virus Egress. Viruses, 2019, 11, 25.	1.5	28
290	T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders. International Review of Cell and Molecular Biology, 2019, 342, 175-263.	1.6	6
291	PREVAIL I Cluster Vaccination Study With rVSV ^Δ G-ZEBOV-GP as Part of a Public Health Response in Liberia. Journal of Infectious Diseases, 2019, 219, 1634-1641.	1.9	12
292	Second generation of diazachrysenes: Protection of Ebola virus infected mice and mechanism of action. European Journal of Medicinal Chemistry, 2019, 162, 32-50.	2.6	15
293	A Smartphone-Based Rapid Telemonitoring System for Ebola and Marburg Disease Surveillance. ACS Sensors, 2019, 4, 61-68.	4.0	23
294	Identification of novel HLA-A11-restricted T-cell epitopes in the Ebola virus nucleoprotein. Microbes and Infection, 2019, 21, 56-62.	1.0	6
295	Ebola Virus Disease in Great Apes. , 2019, , 233-238.		0
296	Considerations for use of Ebola vaccine during an emergency response. Vaccine, 2019, 37, 7190-7200.	1.7	23
297	Quality improvement of health systems in an epidemic context: A framework based on lessons from the Ebola virus disease outbreak in West Africa. International Journal of Health Planning and Management, 2020, 35, 52-67.	0.7	3
298	Ebola and Marburg Virus: A Brief Review. , 2020, , 201-218.		0
299	Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults. Journal of Infectious Diseases, 2020, 222, 572-582.	1.9	38
300	Ebola Vaccines: Biomedical Advances, Human Rights Challenges. Journal of Infectious Diseases, 2020, 222, 521-524.	1.9	4

#	ARTICLE	IF	CITATIONS
301	Viral Hemorrhagic Fevers. , 2020, , 351-381.		0
302	Plant Virus-Based Nanotechnologies. Women in Engineering and Science, 2020, , 57-69.	0.2	5
303	Why are vaccines against many human viral diseases still unavailable; an historic perspective?. Journal of Medical Virology, 2020, 92, 129-138.	2.5	25
304	Ebola Virus in the Democratic Republic of the Congo. Chest, 2020, 157, 42-46.	0.4	9
305	Description of vaccine clinical trials in Africa: a narrative review. Human Vaccines and Immunotherapeutics, 2020, 16, 972-980.	1.4	8
306	Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report. Clinical Infectious Diseases, 2020, 71, 2872-2879.	2.9	17
307	Missed vaccinations and critical care admission: all you may wish to know or rediscoverâ€”a narrative review. Intensive Care Medicine, 2020, 46, 202-214.	3.9	7
308	Towards quantification of protective antibody responses by passive transfer of the 1st WHO International Standard for Ebola virus antibody in a guinea pig model. Vaccine, 2020, 38, 345-349.	1.7	4
309	Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda. Global Health Action, 2020, 13, 1829829.	0.7	7
310	Modelling the daily risk of Ebola in the presence and absence of a potential vaccine. Infectious Disease Modelling, 2020, 5, 905-917.	1.2	5
311	Estudio de un episodio epidÃ©mico infeccioso. EMC - PodologÃ­a, 2020, 22, 1-9.	0.1	1
312	An Overview of the Progress Made on the Coronavirus Vaccine. E3S Web of Conferences, 2020, 185, 03042.	0.2	0
313	Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines. Npj Vaccines, 2020, 5, 88.	2.9	21
314	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. Microorganisms, 2020, 8, 1473.	1.6	12
315	Characterization of rVSV-G-ZEBOV-GP glycoproteins using automated capillary western blotting. Vaccine, 2020, 38, 7166-7174.	1.7	11
316	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. Seminars in Oncology, 2020, 47, 305-308.	0.8	10
317	Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks. American Journal of Epidemiology, 2020, 189, 1324-1332.	1.6	7
318	Clinical trials in the time of a pandemic. Clinical Trials, 2020, 17, 467-471.	0.7	5

#	ARTICLE	IF	CITATIONS
319	A stochastic threshold of a delayed epidemic model incorporating Lévy processes with harmonic mean and vaccination. <i>International Journal of Biomathematics</i> , 2020, 13, 2050069.	1.5	9
320	Computational design of a potential multi-epitope subunit vaccine using immunoinformatics to fight Ebola virus. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104464.	1.0	15
321	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 483-497.	0.6	40
322	Development and Applications of Viral Vected Vaccines to Combat Zoonotic and Emerging Public Health Threats. <i>Vaccines</i> , 2020, 8, 680.	2.1	50
323	Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. <i>Viruses</i> , 2020, 12, 1324.	1.5	35
324	New viral vectors for infectious diseases and cancer. <i>Seminars in Immunology</i> , 2020, 50, 101430.	2.7	55
325	Cationic Polymers for the Delivery of the Ebola DNA Vaccine Encoding Artificial T-Cell Immunogen. <i>Vaccines</i> , 2020, 8, 718.	2.1	19
327	Dangerous Pathogens as a Potential Problem for Public Health. <i>Medicina (Lithuania)</i> , 2020, 56, 591.	0.8	16
328	AAV Vected Immunoprophylaxis for Filovirus Infections. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 169.	0.9	11
329	Pandemic vaccine trials: expedite, but don't rush. <i>Research Ethics</i> , 2020, 16, 1-12.	0.8	3
330	Next-generation vaccine platforms for COVID-19. <i>Nature Materials</i> , 2020, 19, 810-812.	13.3	276
331	Re-emergency of Ebola in the Democratic Republic of Congo: synergizing the preparedness and response measures with the sustainable development goals. <i>Disaster Prevention and Management</i> , 2020, 29, 649-662.	0.6	0
332	Self-Amplifying RNA Viruses as RNA Vaccines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5130.	1.8	54
333	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1817.	2.2	189
334	Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. <i>Cell Host and Microbe</i> , 2020, 28, 465-474.e4.	5.1	156
335	Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment. <i>Nature Communications</i> , 2020, 11, 3736.	5.8	11
336	Estimating the protective effect of case isolation with transmission tree reconstruction during the Ebola outbreak in Nigeria, 2014. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20200498.	1.5	4
337	Transforming vaccine development. <i>Seminars in Immunology</i> , 2020, 50, 101413.	2.7	35

#	ARTICLE	IF	CITATIONS
338	Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. <i>Microbes and Infection</i> , 2020, 22, 515-524.	1.0	23
339	Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. <i>Viruses</i> , 2020, 12, 915.	1.5	13
340	Vaccines for COVID-19. <i>Clinical and Experimental Immunology</i> , 2020, 202, 162-192.	1.1	185
341	Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26 and Modified Vaccinia Ankara Vectors Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 595-607.	1.9	27
342	Ervebo (Ebola Zaire Vaccine, Live/rVSV-G-ZEBOV-GP): The First Licensed Vaccine for the Prevention of Ebola Virus Disease. <i>Journal of Pharmacy Technology</i> , 2020, 36, 243-250.	0.5	12
343	Marburg virus disease: A summary for clinicians. <i>International Journal of Infectious Diseases</i> , 2020, 99, 233-242.	1.5	67
344	Recent successes in therapeutics for Ebola virus disease: no time for complacency. <i>Lancet Infectious Diseases</i> , 2020, 20, e231-e237.	4.6	42
345	Vaccination of contacts of Ebola virus disease survivors to prevent further transmission. <i>The Lancet Global Health</i> , 2020, 8, e1455-e1456.	2.9	6
346	Public health emergencies of international concern: a historic overview. <i>Journal of Travel Medicine</i> , 2020, 27, .	1.4	116
347	Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures. <i>Vaccine</i> , 2020, 38, 7949-7955.	1.7	8
348	Viral genomics in Ebola virus research. <i>Nature Reviews Microbiology</i> , 2020, 18, 365-378.	13.6	30
349	Ethical considerations for epidemic vaccine trials. <i>Journal of Medical Ethics</i> , 2020, 46, 465-469.	1.0	19
350	Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. <i>Vaccine</i> , 2020, 38, 4601-4608.	1.7	10
351	Ebola. <i>New England Journal of Medicine</i> , 2020, 382, 1832-1842.	13.9	128
352	Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine. <i>Vaccines</i> , 2020, 8, 215.	2.1	3
353	Arranging good clinical practices training and trial monitoring for a vaccine efficacy study during a public health emergency of international concern. <i>Vaccine</i> , 2020, 38, 4050-4056.	1.7	1
354	Which interventions work best in a pandemic?. <i>Science</i> , 2020, 368, 1063-1065.	6.0	114
355	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. <i>Immunology</i> , 2020, 160, 223-232.	2.0	86

#	ARTICLE	IF	CITATIONS
356	Filoviruses Use the HOPS Complex and UVRAG To Traffic to Niemann-Pick C1 Compartments during Viral Entry. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
357	Humoral and cellular immune response induced by rVSV ^Î G-ZEBOV-GP vaccine among frontline workers during the 2013â€“2016 West Africa Ebola outbreak in Guinea. <i>Vaccine</i> , 2020, 38, 4877-4884.	1.7	14
358	Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. <i>Npj Vaccines</i> , 2020, 5, 51.	2.9	49
359	Vaccines for COVID-19: The current state of play. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 43-49.	1.2	170
360	Managing enduring public health emergencies such as COVID-19: lessons from Uganda Red Cross Societyâ€™s Ebola virus disease response operation. <i>BMJ Leader</i> , 2020, 4, 113-116.	0.8	11
361	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. <i>Vaccines</i> , 2020, 8, 241.	2.1	12
362	A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region. <i>MBio</i> , 2020, 11, .	1.8	18
363	Use of antiviral drugs to reduce COVID-19 transmission. <i>The Lancet Global Health</i> , 2020, 8, e639-e640.	2.9	175
364	Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. <i>F1000Research</i> , 0, 9, 72.	0.8	37
365	A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition. <i>Journal of Virology</i> , 2020, 94, .	1.5	7
366	Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus â€“ Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis. <i>Vaccine</i> , 2020, 38, 4885-4891.	1.7	12
367	A tool with many applications: vesicular stomatitis virus in research and medicine. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1187-1201.	1.4	35
368	Development of a TB vaccine trial site in Africa and lessons from the Ebola experience. <i>BMC Public Health</i> , 2020, 20, 999.	1.2	1
369	Public Health Program for Decreasing Risk for Ebola Virus Disease Resurgence from Survivors of the 2013â€“2016 Outbreak, Guinea. <i>Emerging Infectious Diseases</i> , 2020, 26, 206-211.	2.0	4
370	Safety, immunogenicity and riskâ€“benefit analysis of rVSV-Î ^Î G-ZEBOV-GP (V920) Ebola vaccine in Phase Iâ€“III clinical trials across regions. <i>Future Microbiology</i> , 2020, 15, 85-106.	1.0	23
371	The 2018/19 Ebola epidemic the Democratic Republic of the Congo (DRC): epidemiology, outbreak control, and conflict. <i>Infection Prevention in Practice</i> , 2020, 2, 100038.	0.6	14
372	Incubation periods impact the spatial predictability of cholera and Ebola outbreaks in Sierra Leone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5067-5073.	3.3	28
373	Ebola virus disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 13.	18.1	340

#	ARTICLE	IF	CITATIONS
374	Uncovering the Anti-Ebola Repertome. <i>Cell Host and Microbe</i> , 2020, 27, 163-165.	5.1	0
375	Examination of the effect of agitation on the potency of the Ebola Zaire vaccine rVSV Δ G-ZEBOV-GP. <i>Vaccine</i> , 2020, 38, 2643-2645.	1.7	8
376	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	17
377	Immune correlates of postexposure vaccine protection against Marburg virus. <i>Scientific Reports</i> , 2020, 10, 3071.	1.6	22
378	Nanoparticle-based delivery of self-amplifying RNA. <i>Gene Therapy</i> , 2020, 27, 183-185.	2.3	4
379	Epidemic models on social networks With inference. <i>Statistica Neerlandica</i> , 2020, 74, 222-241.	0.9	21
380	Prior vaccination with recombinant Vesicular Stomatitis Virus Zaire Ebola virus vaccine is associated with improved survival among patients with Ebolavirus infection. <i>Vaccine</i> , 2020, 38, 3003-3007.	1.7	14
381	Treatment of Ebola-related critical illness. <i>Intensive Care Medicine</i> , 2020, 46, 285-297.	3.9	15
383	Characterization and analytical validation of a new antigenic rapid diagnostic test for Ebola virus disease detection. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007965.	1.3	16
384	Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 455-466.	4.6	22
385	Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 759-778.	2.6	32
386	Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections. <i>Expert Review of Vaccines</i> , 2020, 19, 85-103.	2.0	4
387	Exposure to Ebola Virus and Risk for Infection with Malaria Parasites, Rural Gabon. <i>Emerging Infectious Diseases</i> , 2020, 26, 229-237.	2.0	7
388	Designing a Study of Correlates of Risk for Ebola Vaccination. <i>American Journal of Epidemiology</i> , 2020, 189, 747-754.	1.6	2
389	Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X Δ , ϕ hydro fixed-bed. <i>Journal of Biotechnology</i> , 2020, 310, 32-39.	1.9	24
390	Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 388-389.	4.6	3
391	High-Throughput, High-Resolution Interferometric Light Microscopy of Biological Nanoparticles. <i>ACS Nano</i> , 2020, 14, 2002-2013.	7.3	26
392	Making Emergency Use of Experimental Vaccines Safer. <i>AMA Journal of Ethics</i> , 2020, 22, E43-49.	0.4	1

#	ARTICLE	IF	CITATIONS
393	Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis. PLoS ONE, 2020, 15, e0230406.	1.1	20
394	Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks. Health Security, 2020, 18, 241-249.	0.9	29
395	A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene. MBio, 2020, 11, .	1.8	34
396	Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2020, 20, 707-718.	4.6	45
397	A Vaccine against Ebola Virus. Cell, 2020, 181, 6.	13.5	73
398	Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor. Vaccine, 2020, 38, 3639-3645.	1.7	9
399	Ebola vaccine? Family first! Evidence from using a brief measure on Ebola vaccine demand in a national household survey during the outbreak in Sierra Leone. Vaccine, 2020, 38, 3854-3861.	1.7	4
400	New paths for sustainable solutions to tackle global and emerging infectious threats. Biologicals, 2020, 65, 42-45.	0.5	0
401	Messenger RNA-Based Vaccines Against Infectious Diseases. Current Topics in Microbiology and Immunology, 2020, , 111-145.	0.7	43
402	Extraordinary diseases require extraordinary solutions. Vaccine, 2020, 38, 3987-3988.	1.7	62
403	Ethics of Conducting Clinical Research in an Outbreak Setting. Annual Review of Virology, 2020, 7, 475-494.	3.0	10
404	Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. Cmaj, 2020, 192, E405-E407.	0.9	36
405	Influence and prioritization of non-epistemic values in clinical trial designs: a study of Ebola Æsa Suffit trial. SynthÃse, 2021, 198, 2393-2409.	0.6	6
406	Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine, 2021, 39, 85-120.	1.7	111
407	Oncolytic virotherapy: Challenges and solutions. Current Problems in Cancer, 2021, 45, 100639.	1.0	51
408	Considerations on the clinical development of COVID-19 vaccine from trial design perspectives. Human Vaccines and Immunotherapeutics, 2021, 17, 656-660.	1.4	3
409	Highly targeted spatiotemporal interventions against cholera epidemics, 2000â€19: a scoping review. Lancet Infectious Diseases, The, 2021, 21, e37-e48.	4.6	19
410	Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus. Critical Reviews in Microbiology, 2021, 47, 112-125.	2.7	63

#	ARTICLE	IF	CITATIONS
411	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 493-506.	4.6	115
412	COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. <i>International Immunopharmacology</i> , 2021, 90, 107247.	1.7	87
413	What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e26-e35.	4.6	500
414	Presence of Ebola virus in breast milk and risk of mother-to-child transmission: synthesis of evidence. <i>Annals of the New York Academy of Sciences</i> , 2021, 1488, 33-43.	1.8	13
415	How attitudes towards vaccination change in the face of an outbreak. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 805-809.	1.4	4
416	Review of Ebola virus disease in children – how far have we come?. <i>Paediatrics and International Child Health</i> , 2021, 41, 12-27.	0.3	5
417	Multivalent Glycosylated Carbon Nanostructures: Efficient Inhibitors of Emergent Viruses Infection. <i>RSC Nanoscience and Nanotechnology</i> , 2021, , 56-97.	0.2	2
418	Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. <i>Vaccines</i> , 2021, 9, 67.	2.1	10
419	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-12.	26.7	37
420	How Vaccinating People Can Also Protect Others. , 2021, , 15-20.		0
421	Ebola virus antibody decay – stimulation in a high proportion of survivors. <i>Nature</i> , 2021, 590, 468-472.	13.7	30
423	COVID-19 Pandemic and Vaccines. , 2021, , 205-235.		2
425	The COVID-19 Vaccine Landscape. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 549-573.	0.8	9
426	Looking beyond COVID-19 vaccine phase 3 trials. <i>Nature Medicine</i> , 2021, 27, 205-211.	15.2	473
427	No Evidence of rVSV-Ebola Virus Vaccine Replication or Dissemination in the Sand Fly <i>Phlebotomus papatasi</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	1
429	Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection. <i>Clinical and Translational Medicine</i> , 2021, 11, e331.	1.7	9
430	Biosecurity risks associated with vaccine platform technologies. <i>Vaccine</i> , 2022, 40, 2514-2523.	1.7	9
431	Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. <i>Nature Communications</i> , 2021, 12, 1153.	5.8	10

#	ARTICLE	IF	CITATIONS
432	The Key Role of Nucleic Acid Vaccines for One Health. <i>Viruses</i> , 2021, 13, 258.	1.5	19
434	Estimation of the correlates of protection of the rVSVÎ”G-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. <i>Lancet Microbe, The</i> , 2021, 2, e70-e78.	3.4	19
435	Development of Pandemic Vaccines: ERVEBO Case Study. <i>Vaccines</i> , 2021, 9, 190.	2.1	39
436	Ebola: A review and focus on neurologic manifestations. <i>Journal of the Neurological Sciences</i> , 2021, 421, 117311.	0.3	4
437	SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1626.	1.2	17
438	Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection. <i>Frontiers in Immunology</i> , 2020, 11, 599568.	2.2	16
439	Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. <i>Nature Medicine</i> , 2021, 27, 401-410.	15.2	127
440	Consequences of Phosphorylation in a <i>Mononegavirales</i> Polymerase-Cofactor System. <i>Journal of Virology</i> , 2021, 95, .	1.5	3
441	A Review of the Progress of COVID-19 Vaccine Development. <i>Duzce Universitesi Tip FakÃ¼ltesi Dergisi</i> , 2021, 23, 1-23.	0.3	7
442	Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?. <i>Viruses</i> , 2021, 13, 569.	1.5	3
443	Commentary title: COVID-19 research, Africa, and global health. <i>Journal of Virus Eradication</i> , 2021, 7, 100030.	0.3	1
444	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , 2021, 22, 224.	0.7	8
445	Ebola infection in pregnancy, an ongoing challenge for both the global health expert and the pregnant womanâ€™A review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 258, 111-117.	0.5	1
446	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. <i>Globalization and Health</i> , 2021, 17, 24.	2.4	40
447	The need for a new strategy for Ebola vaccination. <i>Nature Medicine</i> , 2021, 27, 580-581.	15.2	26
448	COVID-19 immunity and vaccines: what a pharmacist needs to know. <i>Asian Biomedicine</i> , 2021, 15, 51-67.	0.2	0
449	Assessing vaccine durability in randomized trials following placebo crossover. <i>Statistics in Medicine</i> , 2021, 40, 5983-6007.	0.8	12
450	Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. <i>Nature Biotechnology</i> , 2021, 39, 989-999.	9.4	13

#	ARTICLE	IF	CITATIONS
451	Ebola Virus Transmission Initiated by Relapse of Systemic Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1240-1247.	13.9	57
452	Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner. <i>Frontiers in Immunology</i> , 2021, 12, 595390.	2.2	16
453	Non-epistemic values in shaping the parameters for evaluating the effectiveness of candidate vaccines: the case of an Ebola vaccine trial. <i>History and Philosophy of the Life Sciences</i> , 2021, 43, 63.	0.6	1
454	Practical handling of allergic reactions to COVID-19 vaccines. <i>Allergo Journal International</i> , 2021, 30, 79-95.	0.9	25
455	Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA. <i>Molecular Frontiers Journal</i> , 2021, 05, 38-57.	0.9	6
456	Demographic and statistical study of covid-19: Transmission and drug susceptibility pattern in India. <i>AIUB Journal of Science and Engineering</i> , 2021, 20, 17-24.	0.3	0
457	Effects of Gamma Irradiation of Human Serum Samples from rVSV ^G -ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1751-1754.	0.6	2
458	The Brighton Collaboration standardized templates for collection of key information for benefit-risk assessment of vaccines by technology (BRAVATO; formerly V3SWG). <i>Vaccine</i> , 2021, 39, 3050-3052.	1.7	3
459	Leveraging Pathogen Sequence and Contact Tracing Data to Enhance Vaccine Trials in Emerging Epidemics. <i>Epidemiology</i> , 2021, 32, 698-704.	1.2	3
460	The role and challenges of cluster randomised trials for global health. <i>The Lancet Global Health</i> , 2021, 9, e701-e710.	2.9	34
461	Monitoring Symptoms of Infectious Diseases: Perspectives for Printed Wearable Sensors. <i>Micromachines</i> , 2021, 12, 620.	1.4	12
462	Bioreactor production of rVSV ^G -based vectors in Vero cell suspension cultures. <i>Biotechnology and Bioengineering</i> , 2021, 118, 2649-2659.	1.7	15
463	Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus ^G -Zaire Ebola Virus Envelope Glycoprotein. <i>Journal of Infectious Diseases</i> , 2021, 224, 1907-1915.	1.9	7
464	Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. <i>Nature Communications</i> , 2021, 12, 2633.	5.8	25
465	Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?. <i>Frontiers in Immunology</i> , 2021, 12, 673699.	2.2	16
467	Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	4
468	Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin ^G -piperazine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial. <i>BMJ Global Health</i> , 2021, 6, e005021.	2.0	7
469	Antibody responses to filovirus infections in humans: protective or not?. <i>Lancet Infectious Diseases</i> , 2021, 21, e348-e355.	4.6	3

#	ARTICLE	IF	CITATIONS
470	Reflections on 40 Years of AIDS. <i>Emerging Infectious Diseases</i> , 2021, 27, 1553-1560.	2.0	49
471	EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1629-1639.	2.7	99
472	Mapping the global research output on Ebola vaccine from research indexed in web of science and scopus: a comprehensive bibliometric analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4246-4258.	1.4	11
473	Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises. <i>Drug Discovery Today</i> , 2021, 26, 2608-2618.	3.2	2
474	Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3771-3783.	1.4	3
475	Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	22
476	An innovative and integrated model for global outbreak response and research - A case study of the UK Public Health Rapid Support Team (UK-PHRST). <i>BMC Public Health</i> , 2021, 21, 1378.	1.2	5
477	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. <i>Frontiers in Immunology</i> , 2021, 12, 706757.	2.2	4
478	Implementation of the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) study: Lessons learned for vision health systems strengthening in Sierra Leone. <i>PLoS ONE</i> , 2021, 16, e0252905.	1.1	5
479	Quantifying Efficiency Gains of Innovative Designs of Two-Arm Vaccine Trials for COVID-19 Using an Epidemic Simulation Model. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 33-41.	0.6	8
480	Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation. <i>Clinical and Translational Science</i> , 2021, 14, 2391-2398.	1.5	6
481	Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention. <i>Frontiers in Immunology</i> , 2021, 12, 690976.	2.2	4
482	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
483	Characterization of an Anti-Ebola virus Hyperimmune Globulin Derived from Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2021, , .	1.9	3
484	Vesicular Stomatitis Virus: From Agricultural Pathogen to Vaccine Vector. <i>Pathogens</i> , 2021, 10, 1092.	1.2	29
485	Ebola virus disease: current vaccine solutions. <i>Current Opinion in Immunology</i> , 2021, 71, 27-33.	2.4	52
486	Safety of a Novel <i>Listeria monocytogenes</i> -Based Vaccine Vector Expressing NcSAG1 (<i>Neospora caninum</i>) Tj ETQq0 0.0 rgBT /Overlock 10	1.8	9
487	Exploration of alternate therapeutic remedies in Ebola virus disease: the case of reported antiviral phytochemical derived from the leaves <i>Spondias Mombin</i> Linn. <i>Advances in Traditional Medicine</i> , 0, , 1.	1.0	1

#	ARTICLE	IF	CITATIONS
488	Zoonotic risk factors associated with seroprevalence of Ebola virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of Congo. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009566.	1.3	4
489	Immunization Update 2021. <i>Pharmacy Today</i> , 2021, 27, 52-62.	0.0	0
490	Potential test-negative design study bias in outbreak settings: application to Ebola vaccination in Democratic Republic of Congo. <i>International Journal of Epidemiology</i> , 2022, 51, 265-278.	0.9	1
491	Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses. <i>Frontiers in Immunology</i> , 2021, 12, 703986.	2.2	23
492	Recent SARS-CoV-2 Outlook and Implications in a COVID-19 Vaccination Era. <i>Infectious Microbes & Diseases</i> , 2021, 3, 125-133.	0.5	0
493	Single dose rVSVΔ ^G -JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge. <i>Npj Vaccines</i> , 2021, 6, 96.	2.9	1
494	Herramientas biotecnológicas en el diagnóstico, prevención y tratamiento frente a pandemias. <i>Revista Bionatura</i> , 2021, 3, 2091-2113.	0.1	0
495	Vesicular Stomatitis Virus Chimeras Expressing the Oropouche Virus Glycoproteins Elicit Protective Immune Responses in Mice. <i>MBio</i> , 2021, 12, e0046321.	1.8	9
496	Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. <i>Frontiers in Immunology</i> , 2021, 12, 721328.	2.2	28
497	Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. <i>Pathogens</i> , 2021, 10, 1201.	1.2	9
498	Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 110-122.	4.6	48
499	Ebola Virus Disease, Diagnostics and Therapeutics: Where is the Consensus in Over Three Decades of Clinical Research?. <i>Scientific African</i> , 2021, 13, e00862.	0.7	1
500	Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program. <i>International Journal of Infectious Diseases</i> , 2021, 113, 166-167.	1.5	9
502	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 97-109.	4.6	47
503	Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions. <i>IEEE Transactions on Molecular, Biological, and Multi-Scale Communications</i> , 2021, 7, 121-141.	1.4	16
504	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
505	Selection of Filovirus Isolates for Vaccine Development Programs. <i>Vaccines</i> , 2021, 9, 1045.	2.1	6
506	Is Guinea meeting the challenges to control the new ebola virus disease outbreak in West Africa?. <i>Preventive Medicine Reports</i> , 2021, 23, 101394.	0.8	4

#	ARTICLE	IF	CITATIONS
507	The 2013–2016 Ebola virus disease outbreak in West Africa. <i>Current Opinion in Pharmacology</i> , 2021, 60, 360-365.	1.7	16
508	Africa's preparedness towards COVID-19 vaccines: Demand and acceptability challenges. <i>Current Research in Behavioral Sciences</i> , 2021, 2, 100048.	2.4	5
509	A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease. <i>Current Opinion in Pharmacology</i> , 2021, 61, 28-35.	1.7	0
510	High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. <i>Emerging Microbes and Infections</i> , 2021, 10, 651-663.	3.0	5
511	Immunological mechanisms associated with clinical features of Ebola virus disease and its control and prevention. , 2021, , 159-183.		0
513	Inside the story about the research and development of COVID-19 vaccines. <i>Clinical and Experimental Vaccine Research</i> , 2021, 10, 154.	1.1	11
514	Partnership for Research on Ebola VACCination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. <i>Trials</i> , 2021, 22, 86.	0.7	9
515	The Real-World Ethics of Adaptive-Design Clinical Trials. <i>Hastings Center Report</i> , 2017, 47, 27-37.	0.7	18
516	Accelerating Vaccine Development During the 2013–2016 West African Ebola Virus Disease Outbreak. <i>Current Topics in Microbiology and Immunology</i> , 2017, 411, 229-261.	0.7	14
518	Ebola and Pregnant Women: Providing Maternity Care at MSF Treatment Centers. <i>Global Maternal and Child Health</i> , 2019, , 87-101.	0.1	2
519	Coronaviruses pandemics: Can neutralizing antibodies help?. <i>Life Sciences</i> , 2020, 255, 117836.	2.0	24
520	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. <i>Npj Vaccines</i> , 2020, 5, 112.	2.9	45
521	Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 994-1002.	1.4	7
522	COVID-19's impact on travel medicine surpasses that of all other emerging viral diseases. <i>Journal of Travel Medicine</i> , 2020, 27, .	1.4	5
523	Ebola returns to its Congo Basin heartland. <i>Journal of General Virology</i> , 2018, 99, 861-863.	1.3	2
524	Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana) Tj ETQq1 1 0.784314rgBT /Overlock 10	1.3	0
533	Clinical trial design: The nobility of randomization. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	2
534	Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. <i>Journal of Clinical Investigation</i> , 2019, 130, 539-551.	3.9	40

#	ARTICLE	IF	CITATIONS
535	Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 3936-3946.	3.9	12
536	Panic prescribing has become omnipresent during the COVID-19 pandemic. <i>Journal of Clinical Investigation</i> , 2020, 130, 2752-2753.	3.9	8
537	Lassa virus diversity and feasibility for universal prophylactic vaccine. <i>F1000Research</i> , 2019, 8, 134.	0.8	29
538	Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. <i>F1000Research</i> , 2020, 9, 72.	0.8	251
539	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018, 13, e0192312.	1.1	64
542	Pandemics: Risks, Impacts, and Mitigation. , 2017, , 315-345.		280
544	An Insight into Nanomedicinal Approaches to Combat Viral Zoonoses. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 915-962.	1.0	2
545	Data Fitting and Scenario Analysis of Vaccination in the 2014 Ebola Outbreak in Liberia. <i>Osong Public Health and Research Perspectives</i> , 2019, 10, 187-201.	0.7	8
547	Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design. <i>Journal of Epidemiology and Global Health</i> , 2021, 11, 15.	1.1	4
548	Virus-Vectored Ebola Vaccines. <i>Acta Naturae</i> , 2017, 9, 4-11.	1.7	24
549	Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas. <i>Vaccines</i> , 2020, 8, 38.	2.1	31
550	The potential impact of a prophylactic vaccine for Ebola in Sierra Leone. <i>Mathematical Biosciences and Engineering</i> , 2017, 15, 337-359.	1.0	19
551	Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 207-213.	0.6	12
552	Mechanisms of Immune Evasion by Ebola Virus. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 15-22.	0.8	6
553	The Interaction of Ebola Virus with the Immune System Ebola and Immunity. , 2021, , .		0
554	Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. <i>Vaccines</i> , 2021, 9, 1187.	2.1	30
555	VSV-EBOV Induces Temporal and Dose-Dependent Transcriptional Responses in Non-human Primates. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	0
556	Pandemics One Health preparedness for the next. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100210.	3.0	22

#	ARTICLE	IF	CITATIONS
557	Intracluster correlation coefficients in a large cluster randomized vaccine trial in schools: Transmission and impact of shared characteristics. PLoS ONE, 2021, 16, e0254330.	1.1	0
558	Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease. Frontiers in Immunology, 2021, 12, 774026.	2.2	32
559	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. Vaccines, 2021, 9, 1196.	2.1	15
560	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Human Vaccines and Immunotherapeutics, 2021, 17, 4328-4344.	1.4	13
562	Challenges of evaluating and modelling vaccination in emerging infectious diseases. Epidemics, 2021, 37, 100506.	1.5	14
565	Cutting the Stone: Health Defined in the Era of Value-based Care. Cureus, 2017, 9, e1023.	0.2	0
566	Ebola evolution during the 2013-2016 outbreak. Peer Community in Evolutionary Biology, 2018, , 100019.	0.0	0
567	Ebola vaccine could get first real-world test in emerging outbreak. Nature, 0, , .	13.7	0
568	Ebola vaccine approved for use in ongoing outbreak. Nature, 0, , .	13.7	6
569	Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): Ebola virus disease. EFSA Journal, 2017, 15, e04890.	0.9	1
571	Ebola Hemorrhagic Fever: Recent Update On Disease Status, Current Therapies And Advances In Treatment. Journal of Pharmaceutical Technology Research and Management, 2017, 5, 217-234.	0.3	1
580	Immune Response in Human Pathology: Infections Caused by Bacteria, Viruses, Fungi, and Parasites. , 2019, , 165-178.		2
586	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Medicine, 2021, 18, e1003813.	3.9	34
587	Inhibition of Primed Ebola Virus Glycoprotein by Peptide Compound Conjugated to HIV-1 Tat Peptide Through a Virtual Screening Approach. Lecture Notes in Computer Science, 2020, , 153-165.	1.0	0
588	Risk Factors for Ebola Exposure in Health Care Workers in Boende, Tshuapa Province, Democratic Republic of the Congo. Journal of Infectious Diseases, 2022, 226, 608-615.	1.9	6
589	Public health updates from October 2019 to April 2020. Indian Journal of Community and Family Medicine, 2020, 6, 74.	0.0	0
594	Response to Globally Concerned Infectious Diseases. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 617-625.	0.0	0
595	Establishing Healthcare Worker Performance and Safety in Providing Critical Care for Patients in a Simulated Ebola Treatment Unit: Non-Randomized Pilot Study. Viruses, 2021, 13, 2205.	1.5	1

#	ARTICLE	IF	CITATIONS
596	Electronic Data Management for Vaccine Trials in Low Resource Settings: Upgrades, Scalability, and Impact of ODK. <i>Frontiers in Public Health</i> , 2021, 9, 665584.	1.3	7
597	Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity. <i>Current Opinion in Virology</i> , 2021, 51, 179-189.	2.6	7
598	COVID-19 Outbreak in Africa: Lessons and Insights from the West African Ebola Virus Disease Epidemics. <i>International Journal of Travel Medicine and Global Health</i> , 2020, 8, 96-99.	0.1	0
600	Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-12.	26.7	0
601	Specific Infectious Diseases. , 2023, , 51-146.		0
602	Virus-Vectored Ebola Vaccines. <i>Acta Naturae</i> , 2017, 9, 4-11.	1.7	3
603	Diagnostic and therapeutic implements based on advanced Biotechnology should be available in low-income countries. <i>Acta Biomedica</i> , 2019, 90, 5-6.	0.2	1
604	Prevention of Emerging Infections in Children. <i>Pediatric Clinics of North America</i> , 2022, 69, 185-202.	0.9	2
605	Adapt to Translate. <i>European Journal of Analytic Philosophy</i> , 2021, 17, 5-24.	0.8	3
606	Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo. <i>Vaccine</i> , 2021, , .	1.7	0
607	Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures. <i>Vaccines</i> , 2021, 9, 1335.	2.1	15
610	Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 389.	7.1	21
611	Vaccine Development in the Midst of Ebola Virus Disease Outbreaks. <i>RSC Drug Discovery Series</i> , 2021, , 121-165.	0.2	0
612	Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies. <i>RSC Drug Discovery Series</i> , 2021, , 91-120.	0.2	0
613	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. <i>Frontiers in Immunology</i> , 2021, 12, 788235.	2.2	11
614	Development of the PREDS Score to Predict In-Hospital Mortality of Patients With Ebola Virus Disease Under Advanced Supportive Care: Results From the EVISTA Cohort in the Democratic Republic of the Congo. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
615	Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 212-224.	0.2	0
617	Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, .	1.1	1

#	ARTICLE	IF	CITATIONS
618	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	3.9	27
619	Filoviruses: modern solutions to life-threatening infections. , 2022, , 369-394.		0
620	The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks. <i>Clinical Trials</i> , 2022, 19, 402-406.	0.7	7
621	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. <i>EBioMedicine</i> , 2022, 75, 103810.	2.7	17
622	Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. <i>MBio</i> , 2022, 13, e0337921.	1.8	18
623	Is it time to reconsider ring vaccination for COVID-19?. <i>Cmaj</i> , 2022, 194, E19-E19.	0.9	0
624	Immunogenicity of a recombinant VSV-Vectored SARS-CoV vaccine induced robust immunity in rhesus monkeys after single-dose immunization. <i>Virologica Sinica</i> , 2022, 37, 248-255.	1.2	3
626	Immunogenicity of rVSV ^Δ G-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
627	Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. <i>Journal of Controlled Release</i> , 2022, 343, 361-378.	4.8	11
628	Transcriptomic signatures induced by the Ebola virus vaccine rVSV ^Δ G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. <i>Lancet Microbe</i> , The, 2022, 3, e113-e123.	3.4	6
629	Tracking ebolavirus genomic drift with a resequencing microarray. <i>PLoS ONE</i> , 2022, 17, e0263732.	1.1	1
630	Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada. <i>JAMA Network Open</i> , 2022, 5, e2147042.	2.8	2
631	Current state of Ebola virus vaccines: A snapshot. <i>PLoS Pathogens</i> , 2021, 17, e1010078.	2.1	59
632	Vaccines against SARS-CoV-2. , 2022, , 201-222.		0
633	Self-replicating vehicles based on negative strand RNA viruses. <i>Cancer Gene Therapy</i> , 2022, , .	2.2	3
634	COVID-19 Vaccines: An Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 72.	1.6	32
635	The trillion dollar vaccine gap. <i>Science Translational Medicine</i> , 2022, 14, eabn4342.	5.8	14
636	Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo. <i>BMJ Open</i> , 2022, 12, e055596.	0.8	13

#	ARTICLE	IF	CITATIONS
637	Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein. <i>Vaccines</i> , 2022, 10, 533.	2.1	5
638	Development and Structural Analysis of Antibody Therapeutics for Filoviruses. <i>Pathogens</i> , 2022, 11, 374.	1.2	7
639	WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations. <i>Vaccine</i> , 2022, 40, 2140-2149.	1.7	11
640	The required size of cluster randomized trials of nonpharmaceutical interventions in epidemic settings. <i>Statistics in Medicine</i> , 2022, , .	0.8	1
641	Utilization of Viral Vector Vaccines in Preparing for Future Pandemics. <i>Vaccines</i> , 2022, 10, 436.	2.1	4
642	Identification of novel Ebola virus inhibitors using biologically contained virus. <i>Antiviral Research</i> , 2022, 200, 105294.	1.9	5
643	Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. <i>Journal of Medical Economics</i> , 2021, 24, 1-13.	1.0	4
644	The discovery and development of novel treatment strategies for filoviruses. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 139-149.	2.5	9
645	Ebolavirus: Infection, Vaccination and Control. <i>Molecular Genetics, Microbiology and Virology</i> , 2021, 36, S55-S64.	0.0	0
646	Global control of COVID-19: good vaccines may not suffice. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2021, 45, 1.	0.6	6
648	Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application. <i>Pharmaceutics</i> , 2021, 13, 2091.	2.0	19
649	Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. <i>Npj Vaccines</i> , 2021, 6, 157.	2.9	8
666	Neutralizing Antibody Titer Test of Ebola Recombinant Protein Vaccine and Gene Vector Vaccine pVR-GP-FC. <i>Biomedical and Environmental Sciences</i> , 2018, 31, 721-728.	0.2	1
667	Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. <i>Viruses</i> , 2022, 14, 975.	1.5	9
668	A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases. <i>Epidemiologic Reviews</i> , 2022, 44, 29-54.	1.3	1
669	Therapeutic and prophylactic applications of self-replicating RNA viruses. <i>Exploration of Immunology</i> , 0, , 264-292.	1.7	1
670	Effect of Recombinant Vesicular Stomatitis Virusâ€Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	4
671	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	2.4	28

#	ARTICLE	IF	CITATIONS
672	A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010433.	1.3	20
674	Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic. <i>Pathogens</i> , 2022, 11, 655.	1.2	5
676	Antibodies to combat viral infections: development strategies and progress. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 676-696.	21.5	68
677	Natural History of Sudan ebolavirus to Support Medical Countermeasure Development. <i>Vaccines</i> , 2022, 10, 963.	2.1	4
678	Projecting vaccine demand and impact for emerging zoonotic pathogens. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
680	The use of viral vectors in vaccine development. <i>Npj Vaccines</i> , 2022, 7, .	2.9	73
681	Ebola virus protein VP40 stimulates IL-12 α and IL-18 α dependent activation of human natural killer cells. <i>JCI Insight</i> , 2022, 7, .	2.3	5
682	A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. <i>Cell Reports</i> , 2022, 40, 111094.	2.9	16
683	Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial. <i>EBioMedicine</i> , 2022, 82, 104138.	2.7	13
684	Applications of self-replicating RNA. <i>International Review of Cell and Molecular Biology</i> , 2022, , .	1.6	3
685	The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps. <i>Vaccines</i> , 2022, 10, 1213.	2.1	11
686	A U.S. Government-Coordinated Effort to Leverage Non-Human Primate Data to Facilitate Ebolavirus Vaccine Development. <i>Vaccines</i> , 2022, 10, 1201.	2.1	1
688	A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats. <i>Clinical Trials</i> , 2022, 19, 647-654.	0.7	10
689	Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels. <i>Vaccines</i> , 2022, 10, 1263.	2.1	10
690	Refining the DC-targeting vaccination for preventing emerging infectious diseases. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
691	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. <i>Vaccines</i> , 2022, 10, 1384.	2.1	3
692	Multimerization of Ebola GP1 mucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
693	CDC's COVID-19 International Vaccine Implementation and Evaluation Program and Lessons from Earlier Vaccine Introductions. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	3

#	ARTICLE	IF	CITATIONS
694	Biotechnology applications in infectious disease. , 2022, , 115-129.		0
695	Vaccines against Emerging and Neglected Infectious Diseases: An Overview. <i>Vaccines</i> , 2022, 10, 1385.	2.1	8
696	The Diagnostic Accuracy of Rapid Diagnostic Tests for Ebola Virus Disease: a Systematic Review. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	0
697	Enhanced <i>In Vitro</i> and <i>In Vivo</i> Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
698	Lessons Learned from the Development and Roll-Out of the rVSV ^G -ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines. <i>Vaccines</i> , 2022, 10, 1446.	2.1	2
699	Gene Therapy Cargoes Based on Viral Vector Delivery. <i>Current Gene Therapy</i> , 2023, 23, 111-134.	0.9	5
700	Role of Nanomaterials in COVID-19 Prevention, Diagnostics, Therapeutics, and Vaccine Development. <i>Journal of Nanotheranostics</i> , 2022, 3, 151-176.	1.7	4
701	Model-based evaluation of the impact of prophylactic vaccination applied to Ebola epidemics in Sierra Leone and Democratic Republic of Congo. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
702	Immunogenicity of rVSV ^G -ZEBOV-GP Ebola vaccine (ERVEBO [®]) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. <i>Vaccine</i> , 2022, 40, 6599-6606.	1.7	10
703	Development and optimization of biologically contained Marburg virus for high-throughput antiviral screening. <i>Antiviral Research</i> , 2022, 207, 105426.	1.9	1
704	Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development. <i>Biologics</i> , 2022, 2, 226-242.	2.3	2
705	An introduction to the Marburg virus vaccine consortium, MARVAC. <i>PLoS Pathogens</i> , 2022, 18, e1010805.	2.1	22
706	Understanding Immune Responses to Lassa Virus Infection and to Its Candidate Vaccines. <i>Vaccines</i> , 2022, 10, 1668.	2.1	4
707	Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection. <i>Molecular Therapy</i> , 2023, 31, 374-386.	3.7	3
708	Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo. <i>EClinicalMedicine</i> , 2022, 54, 101699.	3.2	2
709	Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 91-102.	4.6	3
710	Filoviruses and Arenaviruses. , 2023, , 1213-1219.e2.		0
711	Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model. <i>EBioMedicine</i> , 2023, 87, 104405.	2.7	5

#	ARTICLE	IF	CITATIONS
712	Recombinant vesicular stomatitis virusâ€“vectored vaccine induces long-lasting immunity against Nipah virus disease. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	7
713	COVID-19 Vaccines: An Updated Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 714.	1.6	11
714	Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2897-2925.	5.7	1
715	Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. <i>Npj Vaccines</i> , 2022, 7, .	2.9	9
716	A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
717	Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling study. <i>Vaccine</i> , 2022, , .	1.7	0
718	Randomized Trial of Vaccines for Zaire Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2022, 387, 2411-2424.	13.9	24
719	The need and challenges for development of vaccines against emerging infectious diseases. <i>Jornal De Pediatria</i> , 2023, 99, S37-S45.	0.9	4
720	Les virus au service de la santÃ©: la vaccination. <i>Medicine/Sciences</i> , 2022, 38, 1052-1060.	0.0	0
722	Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives. <i>Viruses</i> , 2023, 15, 146.	1.5	8
723	The perinatal health challenges of emerging and re-emerging infectious diseases: A narrative review. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
724	Identifying the scope of ethical challenges caused by the Ebola epidemic 2014-2016 in West Africa: a qualitative study. <i>Philosophy, Ethics, and Humanities in Medicine</i> , 2022, 17, .	0.7	0
725	SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
726	Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges. <i>Vaccines</i> , 2023, 11, 268.	2.1	16
727	Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
729	Marburg Virus- A Threat During SARS-CoV-2 Era: A Review. <i>Infectious Disorders - Drug Targets</i> , 2023, 23, .	0.4	4
730	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	23
731	Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. <i>Cell Reports</i> , 2023, 42, 112402.	2.9	6

#	ARTICLE	IF	CITATIONS
733	Viruses of the Filoviridae family. <i>Science and Innovations</i> , 2023, , 30-37.	0.1	0
734	Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina. <i>Frontiers in Virology</i> , 0, 3, .	0.7	2
735	Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. <i>Viruses</i> , 2023, 15, 698.	1.5	20
736	Ebola virus disease (EVD) outbreak re-emergence regulation in East Africa: preparedness and vaccination perspective. <i>International Journal of Surgery</i> , 0, Publish Ahead of Print, .	1.1	3
737	Quantifying the value of viral genomics when inferring who infected whom in the 2014â€“16 Ebola virus outbreak in Guinea. <i>Virus Evolution</i> , 2023, 9, .	2.2	0
738	Application of DNA Replicons in Gene Therapy and Vaccine Development. <i>Pharmaceutics</i> , 2023, 15, 947.	2.0	2
739	Replicating-Competent VSV-Vectored Pseudotyped Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 329-348.	0.8	2
740	Towards achieving transnational research partnership equity: lessons from implementing adaptive platform trials in low- and middle-income countries. <i>Wellcome Open Research</i> , 0, 8, 120.	0.9	3
741	Lessons from Pasteur may help prevent the deadly relapse of Ebola in patients: Using contingency vaccination to avoid Ebola relapse in immune-privileged organs. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
742	Research Progress of Fever with Thrombocytopenia Syndrome. <i>Intensive Care Research</i> , 2023, 3, 172-181.	0.2	3
743	Emerging Pathogenic Viral Infections of the Eye. <i>Annual Review of Vision Science</i> , 2023, 9, 71-89.	2.3	1
745	Projecting the impact of an ebola virus outbreak on endangered mountain gorillas. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
756	Biobanking in Global Health & Research. , 2023, , 325-343.		0
760	Viral vectors engineered for gene therapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , 1-41.	1.6	1
765	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
766	Ebola Vaccines. , 2023, , 311-329.e6.		0
789	Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention. <i>Pediatric Research</i> , 2024, 95, 488-495.	1.1	1
801	The dynamic landscape of emerging viral infections. <i>Pediatric Research</i> , 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
811	Role of miRNA in Ebola diagnosis and therapeutics. , 2024, , 135-163.		0
816	Ebola and Marburg viruses. , 2024, , 2281-2308.		0